The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Med.
Sec. Ophthalmology
Volume 11 - 2024 |
doi: 10.3389/fmed.2024.1451726
Analysis of factors affecting prognosis of the visual acuity and baseline risk factors for subretinal fibrosis in neovascular age-related macular degeneration patients
Provisionally accepted- Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
Background: To evaluate factors affecting visual acuity prognosis in patients with neovascular age-related macular degeneration (nAMD) following anti-vascular endothelial growth factor (anti-VEGF) therapy via intravitreal injection and to identify baseline risk factors for subretinal fibrosis (SF).Methods: A retrospective study of 64 nAMD eyes treated with intravitreal anti-VEGF treatment over 12 months of follow-up was conducted. Demographic and optical coherence tomography characteristics at baseline were recorded to explore the relevant factors affecting visual acuity outcome. Find baseline risk factors for SF development. The primary baseline measures included OCT qualitative and quantitative indicators, and optical coherence tomography angiography (OCTA) quantitative features.Results: BCVA (logMAR) at 12 months was positively correlated with age (r =0.258, p =0.040), baseline BCVA (r= 0.749, P< 0.001), central macular thickness (CMT) (r = 0.413, P < 0.001), subretinal hyperreflective material (SHRM) (r= 0.304, P=0.014), intraretinal fluid (IRF) (r = 0.423, P < 0.001), type 2 macular neovascularization (MNV) (r=0.272, P = 0.029), and ellipsoidal zone breaks (r = 0.299, P = 0.016), and hyperreflective foci (HF) (r =0.264, P=0.035). Eyes with SF had worse baseline BCVA (P < 0.001), greater CMT(P=0.009), and a higher prevalence of IRF (P = 0.005), type 2 MNV (P = 0.001), SHRM (P = 0.012), and HF (P = 0.028). Logistic binary regression analysis showed that baseline BCVA (logMAR) (OR = 0.02, 95% CI: 0.00-0.45, P = 0.013), HF (OR = 0.11, 95% CI: 0.01-0.95, P = 0.045), and type 2 MNV (OR = 0.08, 95% CI: 0.01-0.88, P = 0.039) were independent risk factors of subretinal fibrosis. As for quantitative OCTA parameters, eyes with subretinal fibrosis had a larger microvascular lesion size (P = 0.003), larger vessels area (P = 0.002), higher number of vessel junctions (P = 0.042) and endpoints (P = 0.024), longer total vessel length (P = 0.005), and lower vessel length density (P = 0.042).Conclusion: This study identifiesenplores baseline OCT and OCTA characteristics associated with subretinal fibrosis in nAMD patients. This information can help predict the occurrence and progression of subretinal fibrosis, potentially leading to more personalized treatment approaches for nAMD patients.* Statistically significant (P < 0.05).
Keywords: subretinal fibrosis, neovascular age-related macular degeneration, Risk factors, Optical Coherence Tomography, optical coherence tomography angiography
Received: 19 Jun 2024; Accepted: 11 Nov 2024.
Copyright: © 2024 Liu, Zheng, Sun, Pan, Li, Zhou and Zheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Minming Zheng, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
Chunxing Pan, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
Danting Li, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
Xi Yuan Zhou, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
Zheng Zheng, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.